Exhibit 99.3

HISTORICAL FINANCIAL STATEMENTS OF BEST DOCTORS HOLDINGS, INC.

Index to Consolidated Financial Statements

1

Independent Auditors’ Report

The Board of Directors

Best Doctors Holdings, Inc.:

We have audited the accompanying consolidated financial statements of Best Doctors Holdings, Inc. and its subsidiaries, which comprise the consolidated balance sheets as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, preferred stock and stockholders’ deficit, and cash flows for each of the years in the three-year period ended December 31, 2016, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Best Doctors Holdings, Inc. and its subsidiaries as of December 31, 2016 and 2015, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2016, in accordance with U.S. generally accepted accounting principles.

/s/ KPMG LLP

Cambridge, Massachusetts

May 5, 2017, except for the reclassification of preferred stock as described in Note 11(h), which is as of June 20, 2017.

2

BEST DOCTORS HOLDINGS, INC.

Consolidated Balance Sheets

December 31, 2016 and 2015

(In thousands, except share data)

See accompanying notes to consolidated financial statements.

3

BEST DOCTORS HOLDINGS, INC.

Consolidated Balance Sheets

December 31, 2016 and 2015

(In thousands, except share data)

See accompanying notes to consolidated financial statements.

4

BEST DOCTORS HOLDINGS, INC.

Consolidated Statements of Operations and Comprehensive Loss

Years ended December 31, 2016, 2015, and 2014

(In thousands)

See accompanying notes to consolidated financial statements.

5

BEST DOCTORS HOLDINGS, INC.

Consolidated Statements of Preferred Stock and Stockholders’ Deficit

Years ended December 31, 2016, 2015 and 2014

(In thousands, except share data)

6

BEST DOCTORS HOLDINGS, INC.

Consolidated Statements of Cash Flows

Years ended December 31, 2016, 2015, and 2014

(In thousands)

See accompanying notes to consolidated financial statements.

7

BEST DOCTORS HOLDINGS, INC.

Consolidated Statements of Cash Flows (Continued)

Years ended December 31, 2016, 2015, and 2014

(In thousands)

See accompanying notes to consolidated financial statements.

8

(1) Organization and Nature of Business

Best Doctors Holdings, Inc. (the Company) provides technology innovations and services to help employers, health plans and provider organizations ensure that their members combat medical uncertainty with access to the best medical minds. Core services include, but are not limited to, Critical Care InterConsultation® (addresses the highly complex, time-sensitive needs of members requiring acute, in-patient care via immediate expert guidance), InterConsultation® (provides members and their treating physicians with an in-depth analysis and complete case review from nationally renowned experts in the member’s condition), Ask the ExpertSM (enables members to get specific answers to personal health care questions from nationally renowned experts), and Find a Best DoctorSM (identifies expert physicians best suited to help initiate hands-on care for members who do not yet have a diagnosis, or who are looking for a new treating physician). These services are sold mainly in the United States (U.S.), Europe, Canada and Japan. The Workers Compensation “CatCare Program” and “Legacy Program,” available in the U.S., provide case review with guidance from top experts in trauma, rehabilitation and other specialties, helping to reduce errors and ensure that best practices are being followed (collectively, these services are referred to herein as Services).

On June 30, 2015, the Company sold its insurance business, and as such determined that the insurance business qualified for discontinued operations presentation in these consolidated financial statements. See note 15 to the consolidated financial statements, which includes the presentation of the associated financial position and results of operations of the Company’s insurance operations which have been separately reported as discontinued operations for all periods presented.

(2) Significant Accounting Policies

(a) Basis of Presentation and Principles of Consolidation

The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP).

The consolidated financial statements include the accounts of Best Doctors Holdings, Inc. and its wholly owned subsidiaries.

All intercompany transactions and balances have been eliminated in consolidation.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures in the consolidated financial statements. Estimates also impact the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Foreign Currency

The functional currency for each of the Company’s foreign subsidiaries is the local currency. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted average exchange rate during the period. Cumulative translation gains or losses are included as a separate component of stockholders’ equity and reported as a part of accumulated other comprehensive income.

Foreign currency gains and losses on transactions denominated in a currency other than the respective subsidiary’s functional currency are included in other income (loss) in the accompanying consolidated statements of operations and comprehensive loss.

For the years ended December 31, 2016, 2015 and 2014, the Company recorded foreign currency transaction losses of $236 and $674 and $429, respectively. The Company has not utilized hedging strategies with respect to such foreign exchange exposure.

9

(2) Significant Accounting Policies (Continued)

(d) Comprehensive Loss

Comprehensive loss includes all changes in stockholders’ equity during a period other than those resulting from investments by and distributions to stockholders. Comprehensive loss includes net loss and other comprehensive loss. The Company’s other comprehensive loss includes foreign currency translation adjustments and unrealized loss on investments.

The accumulated balances for each item of other comprehensive loss are as follows:

(e) Services Revenue Recognition

Revenues are recognized when persuasive evidence of an arrangement exists, the services are performed, the price is fixed or determinable, and there is a reasonable assurance of collection. Services revenues, other than per case fees from customers, are recognized ratably over the contract period. Per case fees are recognized when cases are completed.

Certain services revenue contracts entered into by the Company and its customers have measurable performance guarantees that may require the Company to return partial payment to the customer if certain customer service goals or savings are not realized in a given period. The Company has recorded a reserve in accrued expenses of $1,665 and $1,322, and a reduction to service revenue of $360, $881, and $2,002 for the years ended December 31, 2016, 2015 and 2014, respectively, relating to these performance guarantees.

Deferred revenue is recorded in situations where payments are received from customers in advance of providing services. Such amounts are recognized as revenue when the associated services are provided.

(f) Fair Value of Financial Instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurement for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The carrying amounts reported on the consolidated balance sheets for cash and cash equivalents approximate fair value based on the on-demand nature of cash and the short-term maturity and the daily

10

(2) Significant Accounting Policies (Continued)

pricing mechanisms for cash equivalents. Other assets and liabilities with short-term and intermediate-term maturities and defined settlement amounts, including receivables, payables, and accrued liabilities, are reported at their contractual amounts, which approximate fair value. Debt balances, other than convertible notes which are reported using the fair value option, approximate the carrying amount.

(g) Concentration of Credit Risk

The Company places its cash and cash equivalents in highly rated financial institutions, which are continually reviewed by senior management for financial stability. All “noninterest bearing” transaction accounts held in the U.S. are fully insured, regardless of the balance of the account. Generally, the Company’s cash and cash equivalents in U.S. interest-bearing accounts and in foreign countries exceed financial depository insurance limits. Based on the institutions in which funds are held, the Company believes that its cash and cash equivalents are not exposed to significant credit risk.

(h) Cash and Cash Equivalents

Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds as of December 31, 2016 and 2015.

(i) Allowance for Doubtful Accounts

Accounts receivable are presented net of an allowance for doubtful collections of approximately $637 and $292 at December 31, 2016 and 2015, respectively. In determining this allowance, objective evidence that any receivable is uncollectible, as well as a historical pattern of collections on the entire face amount of the portfolio of accounts receivable, is used to estimate what may not be collectible at the balance sheet date.

(j) Property and Equipment

Property and equipment are reported at cost, net of accumulated depreciation, and are depreciated over the assets’ estimated useful lives, primarily 5 years, using the straight-line method. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the asset or the term of the lease. Repairs and maintenance are expensed as incurred.

(k) Internally Developed Software Costs

The Company capitalizes certain costs incurred in connection with developing or modifying software for internal use. Qualifying internally developed software costs are capitalized and amortized over the estimated useful life of the software, typically 5 years. The Company evaluates internally developed software for impairment at least annually, and whenever changes in circumstances indicate impairment could exist.

(l) Goodwill and Intangible Assets

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a business combination and is reviewed for impairment at least annually. Accounting Standards Codification Topic 350, Intangibles — Goodwill and Other, (ASC 350) permits the assessment of qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test required under ASC 350. The qualitative assessment management performs takes into consideration the following factors: general economic conditions, industry specific performance, and changes in carrying value of the reporting unit.

In the first step of the two-step test, the fair value of the reporting unit is compared with its carrying value (including goodwill). If the fair value of the reporting unit is less than its carrying value, an indication of goodwill impairment exists for the reporting unit and the enterprise must perform step two of the impairment test (measurement). In step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation. The residual fair value after this allocation is the implied fair value of the reporting unit goodwill.

11

(2) Significant Accounting Policies (Continued)

Fair value of the reporting unit is determined using income and market methodologies based on management’s estimates of forecasted cash flows and market value. If the fair value of the reporting unit exceeds its carrying value, step two need not be performed.

Goodwill and intangible assets with indefinite lives are evaluated annually for impairment and whenever changes in conditions indicate that the fair value is more likely than not below its carrying value. No impairment charges were recorded during the years ended December 31, 2016, 2015 and 2014 including upon disposal of the Company’s insurance business in June 2015. See note 15.

Identifiable intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives, which are 3 to 10 years from the date of original acquisition. Identifiable intangible assets consist of customer contracts, acquired technology, noncompetition contracts, and trade names. In 2015, the Company accelerated amortization associated with a tradename that will no longer be in use going forward. Refer to note 5.

(m) Long-Lived Assets

Long-lived assets, such as property and equipment, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment expense is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

(n) Stock-Based Compensation

Stock-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors, and nonemployee contractors, with an exercise price greater than or equal to the fair market value of its common stock at the date of the grant. The Company’s stock-based compensation arrangements vest over periods of up to four years.

The Company recorded stock-based compensation expense of $1,399, $2,443 and $1,542 for the years ended December 31, 2016, 2015 and 2014, respectively, which is included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.

The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected option term, expected stock price volatility which is calculated using the volatility rates of comparable companies as the Company is not publicly traded, the risk-free interest rate from U.S. Treasury bonds, and the Company’s expected annual dividend yield. The total fair value is reduced by estimated forfeitures.

(o) Income Taxes

The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recorded based on the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to be in effect

12

(2) Significant Accounting Policies (Continued)

when those temporary differences are expected to reverse. A valuation allowance is established when management believes it is more likely than not that a deferred tax asset will not be realized.

An entity is permitted to recognize the benefits of uncertain tax positions only when the position is more likely than not to be sustained in the event of examination by tax authorities based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority.

(p) Advertising Costs

Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Advertising expenses of $351, $569 and $638 were recorded in fiscal 2016, 2015 and 2014, respectively.

(q) Acquisitions

In an acquisition of a business, acquired assets and liabilities, including any future contingent payments, are recorded at fair value as of the acquisition date, and the difference between the purchase consideration and the net assets acquired is recorded as goodwill. Intangible assets are identified and recognized separately from goodwill. Professional service expenses related to acquisitions are expensed as incurred and included in selling, general and administrative expenses, on the consolidated statements of operations and comprehensive loss.

(r) Fair Value Option

Under the Fair Value Option Subsections of FASB ASC Subtopic 825-10, Financial Instruments — Overall, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in earnings. See notes 6 and 7 to the consolidated financial statements.

(s) Recent Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This ASU requires that debt issuance costs are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts or premiums. The ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company adopted ASU 2015-03 on a prospective basis for the year ended December 31, 2015.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which eliminates the current requirement for companies to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, companies will be required to classify all deferred tax assets and liabilities as noncurrent. The amendment is effective for annual fiscal periods beginning after December 15, 2017, with early adoption permitted. Upon adoption, the ASU may be applied either prospectively or retrospectively to all prior periods presented. The Company adopted ASU 2015-17 during the year ending December 31, 2015, on a prospective basis.

In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires us to recognize revenue when a customer obtains control rather than when we have transferred substantially all risks and rewards of a good or service and requires expanded disclosures. ASU 2014-09, as amended, is effective for us beginning January 1, 2019. We have not yet determined whether we will adopt the provisions of ASU 2014-09 on a retrospective basis or through a cumulative adjustment to equity. We continue to assess the overall impact the adoption of ASU 2014-09 will have on our consolidated financial statements.

13

(2) Significant Accounting Policies (Continued)

In February 2016, the FASB issued ASU No. 2016-02, Leases, replacing existing lease accounting guidance. The new standard introduces a lessee model that would require entities to recognize assets and liabilities for most leases, but recognize expenses on their income statements in a manner similar to current accounting. The ASU does not make fundamental changes to existing lessor accounting. However, it modifies what qualifies as a sales-type and direct financing lease and related accounting and aligns a number of the underlying principles with those of the new revenue standard, ASU No. 2014-09, such as evaluating how collectability should be considered and determining when profit can be recognized. The guidance eliminates existing real estate-specific provisions and requires expanded qualitative and quantitative disclosures. The standard requires modified retrospective transition by which it is applied at the beginning of the earliest comparative period presented in the year of adoption. For Best Doctors, the ASU is effective January 1, 2020. The Company is currently assessing this ASU’s impact on Best Doctors’ consolidated results of operations and financial condition.

In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU No. 2016-09 changed aspects of the accounting for share-based payment award transactions, including: (1) accounting for income taxes; (2) classification of excess tax benefits on the statement of cash flows; (3) forfeitures; (4) minimum statutory tax withholding requirements; and (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes. The provisions of ASU 2016-02 are effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 eliminates Step 2 of the two-step impairment test, which requires entities to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Rather, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value, as computed in Step 1. Entities may continue to perform the qualitative goodwill impairment assessment to determine whether the quantitative impairment test is necessary. The provisions of ASU 2017-04 are effective for annual periods beginning after December 15, 2021, with early adoption permitted for annual goodwill impairment tests performed after January 1, 2017.

(3) Acquisition

On August 29, 2014, the Company completed the acquisition of Rise Health, Inc. (Rise), a leading population health management company. Among other assets, Rise has built a comprehensive technology platform that develops intelligent, actionable insights regarding data at a population health level, and supports care delivery teams in taking action at the member level. Rise also provides tools to help payers and providers manage the transition from fee-for-service to value-based care. Together with Rise, the Company has added increased data integration and advanced analytics capabilities to its medical expertise solutions. Rise was acquired to provide a synergistic technological platform to bring together data analytics and help consumers get the right diagnosis and treatment. The total purchase price for the acquisition was $23,091.

14

(3) Acquisition (Continued)

The Company accounted for the acquisition of Rise as a business combination using the acquisition method. The following table summarizes the consideration issued to acquire Rise, the amounts of identified assets acquired and the liabilities assumed at the acquisition date:

Recognized amounts of identifiable assets acquired and liabilities assumed included:

The Company believes the resulting amount of goodwill reflects the synergistic benefits expected to result from the application of the Company’s experience and resources to the operations at Rise, which the Company believes will lead to enhanced growth and operating margins. Acquisition related costs included in selling, general and administrative expenses were $255.

(4) Related Party Transactions

The Company earns revenues from certain investors in the Company. During fiscal 2016, 2015 and 2014, the Company recorded $914, $668 and $496 of revenue pursuant to such agreements which were included in service revenues in the consolidated statements of operations and comprehensive loss, respectively.

15

(5) Property and Equipment

Property and equipment as of December 31, 2016 and 2015 are as follows:

The Company recorded depreciation and amortization expense of $1,841, $3,401 and $6,297 for the years ended December 31, 2016, 2015 and 2014, respectively.

(6) Goodwill and Intangible Assets

The following table presents the carrying amount of goodwill and indefinite-lived intangible assets.

16

(6) Goodwill and Intangible Assets (Continued)

The following table presents changes in the carrying amount of definite-lived intangible assets for fiscal 2016 and 2015:

Amortization expense of $1,257, $1,623 and $825 was recorded in fiscal 2016, 2015 and 2014, respectively. Included in the 2015 amortization is an impairment charge of $171 related to the abandonment of the Rise Health tradename.

Future annual amortization expense of intangible assets is as follows:

(7) Convertible Notes

2014 Notes

On August 29, 2014, the Company entered into a Loan and Security Agreement for $21,535 of convertible promissory notes (the Convertible Notes or Notes), maturing on August 29, 2019. The Notes were issued to the owners of Rise in connection with the acquisition of Rise by the Company.

17

(7) Convertible Notes (Continued)

The Notes bear interest at 5% per annum, which is payable quarterly in arrears and accrued until the outstanding principal is paid in full at maturity. The notes are voluntarily pre-payable by the Company (in full) at any time and become due 180 days following an initial public offering. The Convertible Notes and any accrued and unpaid interest are convertible at the option of the holder at any time following an initial public offering or change in control into shares of the Company’s common stock, up to a conversion cap. The conversion price is 85% of the consideration per share of Company common stock to be paid in such initial public offering, or consideration per share to be paid in such change of control, determined on a fully diluted basis assuming conversion of all Convertible Notes. The conversion cap is the number of shares of Company common stock equal to the sum of (a) a specified number of shares of Company common stock plus (b) a percentage of the number of additional shares of Company’s common stock issued between July 8, 2014 and the date of such initial public offering or change in control.

Under provisions of the Convertible Notes, without the prior written consent of the majority of the holders of the Notes, the Company shall not (a) repurchase or redeem any stock or other security (other than employee or director stock subject to a stock repurchase agreement or stock restriction agreement upon termination of employment), (b) incur over $16,000 of debt, (c) pay dividends or distributions of over $2,000 in any given year, (d) incur certain indebtedness to affiliates, (e) pay management or similar fees in excess of customary compensation in the ordinary course of business, or (f) enter into affiliate agreements on terms less favorable than third party arms-length terms. The Company also is required to reserve the shares of common stock issuable under the conversion terms of the Convertible Notes.

In November 2015, the Company entered into an amendment with the Note Holders to raise the debt cap to $19,000 and defer payment of interest for 1 year. The Company agreed to raise the interest rate from 5% to 6% for that year. In addition, upon the execution of the amendment in November 2015, the Company issued the lenders warrants to purchase 60,000 shares of common stock at a per share exercise price of $15.63. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $487 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 2.26%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015.

In April 2016, the Company awarded the Note Holders with an additional 30,000 warrants as the Series K financing had not completed in time per the November 2015 amendment. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $235 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 1.88%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015.

Upon issuance, the Company elected to record the Convertible Notes at fair value, which was $19,829 and $18,882 as of December 31, 2016 and 2015, respectively.

The gain recognized in interest income as a result of the change in the fair value of the Company’s Convertible Notes was $350 for the period from December 31, 2015 to December 31, 2016. Contractual interest expense recorded on the Company’s Convertible Notes was $1,258, $1,131 and $363 for 2016, 2015 and 2014, respectively.

18

(7) Convertible Notes (Continued)

Fair Value Option

ASC Subtopic 825-10 provides entities with an option to measure many financial instruments and certain other items at fair value. Under this guidance, unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each reporting period. As a result of the Company electing this option, the Company records the Convertible Notes at fair value. The Company records these notes at fair value in order to measure the liability at an amount that more accurately reflect the current economic environment in which the company operates.

The following table presents the difference between the aggregate fair value and the aggregate unpaid principal balance of the Convertible Notes recorded at fair value:

2016 Notes and Warrants

On May 9, 2016, the Company entered into two Loan Agreements for a total value of $5,000 of subordinated convertible promissory notes (the “2016 Notes”), maturing on May 09, 2020. The 2016 Notes were issued to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P (BBH) in the amount of $400 and $4,620 respectively.

The 2016 Notes bear interest at 15% per annum, which is payable quarterly in arrears and accrued until the outstanding principal is paid in full at maturity. In the event of default, the Company would incur additional interest of 2% per annum. The 2016 Notes contain a make-whole provision whereby if the 2016 Notes are repaid by the Company for any reason prior to the maturity date, an amount equal to the principal amount being repaid by the Company or redeemed by the investor multiplied by 0.75 is due and payable in addition to the unpaid principal and interest. The 2016 Notes are convertible at the option of the holder at any time during the term of the 2016 Notes into shares of the Company’s preferred stock at a conversion price of $20.00 per share. The preferred stock in which the shares are converted are equivalent to the most senior equity security of the Company. The number of shares issuable upon conversion is determined by the total obtained by dividing the outstanding principal amount of the note to be converted by the conversion price. On the commitment date (May 09, 2016), the Series I shares were the most senior shares of the Company.

Under the provisions of the 2016 Notes, without the prior written consent of the majority of the holders of the 2016 Notes, the Company shall not (a) repurchase or redeem any stock or other security (other than employee or director stock subject to a stock repurchase agreement or stock restriction agreement upon termination of employment), (b) incur over $40,000 of debt (including senior indebtedness, but excluding up to an aggregate of $15,000 of initial principal amount of the note), (c) pay dividends or distributions in any given year, (d) incur certain indebtedness to affiliates, (e) pay management or similar fees in excess of customary compensation in the ordinary course of business, or (f) enter into affiliate agreements on terms

19

(7) Convertible Notes (Continued)

less favorable than third party arms-length terms. The Company also is required to reserve for the number of the shares of common stock issuable under the conversion terms of the 2016 Notes.

The 2016 Notes contain a beneficial conversion feature (“BCF”) of $3,296 at commitment date. Because the conversion feature calls for the option to be settled in the most senior series of preferred stock, the conversion option also contains a contingent BCF. The BCF was calculated based on the on the Series I preferred stock, since they were the most senior preferred shares on commitment date. As of the issuance date of the Series K preferred stock, which became the most senior shares of preferred stock, the unamortized portion of the BCF was revised to reflect a BCF value for the conversion into Series K preferred stock of $1,704.

On May 9, 2016, the Company also issued two warrant agreements exercisable into shares of the Company’s common stock equal to a percentage of the fully-diluted capital stock of the Company. The percentages were 0.07599% and 0.92401% for the warrants to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P respectively. If by June 15, 2016, (i) the Company received all required approvals to create a new class of preferred stock that is equivalent to the Company’s most senior class of preferred stock that has terms acceptable to investors and (ii) the beginning of the redemption period for the Company’s Series I preferred stock is delayed until March 31, 2019, the warrant would only have been exercisable for a number of shares of common stock equal to a lower percentage of the Fully-Diluted Capital Stock as of the exercise date. The lower percentages are 0.03799% and 0.46201% related to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P respectively. On December 5, 2016, the warrants became exercisable into 108,912 shares of common stock. The warrants expire on May 09, 2026 and are exercisable at any time.

The warrants were recorded as liabilities on the Company’s balance sheet at fair value, with a corresponding debt discount, and shall be remeasured at fair value at each reporting date. Changes in fair value will be recorded in the Company’s statement of operations and comprehensive loss. The fair value of the warrants was estimated at $1,704 at the issuance date of May 9, 2016 using the Black Scholes model and assuming: (i) expected volatility of 40%, (ii) risk free interest rate of 2.25%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the agreement. All such warrants were outstanding as of December 31, 2016. The fair value of the warrants as of December 31, 2016 was $2,095.

On December 5, 2016, the Series K financing was completed and $5,000 of the 2016 Notes (100% of the 2016 Notes) were converted into 250,000 shares of Series K preferred stock. Upon conversion, BBH elected to have the $438 of accrued interest paid-in-kind in the form of new notes pursuant to the terms of the note agreement. Upon conversion of the 2016 Notes, the Company recorded the immediate accretion of the unamortized discount of $3,409 as interest expense and the balance of the notes was recorded to Series K preferred stock. During the year ended December 31, 2016, the Company recorded total interest expense related to the Notes of $438 in the statement of operations and comprehensive loss.

The $438 of accrued interest paid-in-kind was converted into new notes and there was no discount from warrants or lender fees associated with the new notes. These notes do not have a BCF as the conversion price was $20.00 per share and the fair value of the Series K preferred stock was $20.00 per share.

20

(8) Fair Value Measurements

All financial instruments are measured and reported at fair value. The fair value hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

·                  Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

·                  Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

·                  Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Fair Value Hierarchy

A description of the valuation techniques applied to the Company’s major categories of assets and liabilities measured at fair value on a recurring basis are as follows:

The fair value of the Convertible Notes was determined by utilizing a probability weighted discounted cash flow analysis which took into consideration market and general economic events as well as the Company’s financial results and other data available as of December 31, 2015 and 2016. This analysis determined the amount to be paid on the notes in either cash or shares at the occurrence of certain events in which the Convertible Notes would be converted into shares of the Company’s common stock or would be repaid to the holders of the Notes in cash. The probability weighted discounted cash flow analysis utilized assumptions related to the probability of the occurrence of each of the various events and appropriate discount rates for each of the scenarios.

Given that the valuation of the Convertible Notes utilized several unobservable inputs, the Company determined that the valuation of the Convertible Notes is a Level 3 valuation.

The following table presents a roll-forward of the fair value of Level 3 (significant unobservable inputs) Convertible Notes:

21

(9) Debt

Note Payable and Line of Credit

The Company entered into a Note Payable — Pledge and Assignment Agreement (Loan and Security Agreement) with Silicon Valley Bank (SVB) totaling $5,000 in 2013. In 2014, the Company entered into a line of credit arrangement with SVB for advances up to approximately $3,000, secured by qualifying accounts receivable and subject to certain covenants and additional reporting requirements. LIBOR advances under the arrangement bear interest at the greater of 3.75% or LIBOR plus 2.5%. Prime-rate based advances bear interest at the Prime Rate plus 0.5%. As part of the Loan and Security Agreement, SVB issued standby letters of credit on behalf of the Company. The Company executed amendments to the Loan and Security Agreement during 2015, in which terms were amended to include the following: (i) borrowing capacity of $9,000, (ii) payment of interest only through June 30, 2016, and then straight-line amortization through December 1, 2018, (iii) interest rate for the revolving line of credit equal to the Prime Rate plus 0.5%, and interest for the term loan equal to the Prime Rate plus 0.75%, (iv) prepayment or termination fee of 3% if such payment occurs prior to December 17, 2016, 2% if such payment occurs prior to the December 17, 2017, and 1% if such payment occurs on or after December 17, 2017, (v) final payment fee of 7% of the term loan amount. As of December 31, 2016 and 2015, the outstanding balance for the SVB Loan and Security Agreement was $1,706 and $7,585, respectively. As of December 31, 2016 and 2015 the interest rate for the revolving line and term loan was 4.5% and 4% respectively.

Upon the amendments of the Loan and Security Agreement in December 2015, the Company issued the lenders warrants to purchase 3,199 shares of Preferred Series J at a per share exercise price of $20. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $45 at the issuance date of December 17, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 2.24%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015. The estimated fair value of the warrants at December 31, 2016 and 2015 was $60 and $45, respectively.

Loan Agreement

On April 7, 2015, the Company entered into a loan agreement with Eastward Capital (Loan Agreement) maturing on January 31, 2019. The Loan Agreement required payments of interest through December 2015, at which point straight line amortization commenced for three years. The interest rate is 12.5% per annum, payable monthly. This facility has an 8% final payment fee and the Lender has a second priority security interest in the collateral subordinated to Silicon Valley Bank. As of December 31, 2016 and 2015, the outstanding balance was $7,254 and $10,000, respectively.

In connection with the Loan Agreement, the Company issued Eastward Capital warrants to purchase 50,000 shares of its Series J preferred stock at a per share exercise price of $20.00. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $605 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 1.91%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016, and 2015. The estimated fair value of the warrants at December 31, 2016 and 2015 was $977 and $677, respectively.

22

(9) Debt (Continued)

The Company recorded interest expense of $1,469, $1,669 and $182 in 2016, 2015 and 2014, respectively, related to the Eastward and SVB loan arrangements.

The following is a schedule of approximate future minimum principal payments under all lines of credit and note payable agreements at December 31, 2016:

(10) Stock Option Plans

The Company grants awards under the 2007 Stock Option and Incentive Plan (the 2007 Plan). The 2007 Plan provides for 1,250,000 shares of common stock that may be issued as ISOs, nonqualified stock options, and stock grants. All terminated, repurchased or expired options under prior stock option plans are available for grant under the 2007 Plan. Options under the 2007 Plan may be granted to employees, directors, officers, advisors and consultants, as defined. Nonqualified options and other stock rights may be granted at no less than fair value per share of common stock. ISOs may be granted at no less than fair market value on the date of the grant, as determined by the Company’s Board of Directors, subject to certain limitations, as defined in the 2007 Plan. Options granted under the 2007 Plan are exercisable at varying dates and have terms as determined by the Company’s Board of Directors. As of December 31, 2016 and 2015, there were 111,556 and 96,664 options to purchase shares of common stock available for future grant under the 2007 Plan, respectively.

A summary of combined stock option activity under the option plans is as follows: